HC Wainwright Has Strong Estimate for Adicet Bio Q3 Earnings

Adicet Bio, Inc. (NASDAQ:ACET) – HC Wainwright raised their Q3 2026 earnings estimates for shares of Adicet Bio in a report issued on Monday, August 10th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($2.05) per share for the quarter, up from their prior forecast of ($2.93). The consensus estimate for Adicet Bio’s current full-year earnings is ($8.52) per share. HC Wainwright also issued estimates for Adicet Bio’s Q4 2026 earnings at ($2.12) EPS, FY2026 earnings at ($8.05) EPS, Q1 2027 earnings at ($2.19) EPS, Q2 2027 earnings at ($1.95) EPS, Q3 2027 earnings at ($1.78) EPS, Q4 2027 earnings at ($1.83) EPS and FY2027 earnings at ($7.67) EPS.

Adicet Bio (NASDAQ:ACET) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.99) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.30).

Other research analysts have also recently issued research reports about the stock. Weiss Ratings upgraded shares of Adicet Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, May 26th. Wall Street Zen raised Adicet Bio from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Jefferies Financial Group initiated coverage on Adicet Bio in a research report on Tuesday, May 5th. They set a “buy” rating and a $19.00 target price for the company. Finally, Guggenheim reaffirmed a “buy” rating and set a $90.00 price target (down from $100.00) on shares of Adicet Bio in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $46.80.

Adicet Bio Price Performance

ACET opened at $8.23 on Wednesday. Adicet Bio has a one year low of $6.01 and a one year high of $17.44. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.71 and a quick ratio of 6.71. The company’s 50 day simple moving average is $8.32 and its 200-day simple moving average is $7.81. The stock has a market capitalization of $77.03 million, a P/E ratio of -0.72 and a beta of 1.60.

Institutional Investors Weigh In On Adicet Bio

A number of institutional investors and hedge funds have recently modified their holdings of ACET. NEXTBio Capital Management LP bought a new position in Adicet Bio in the fourth quarter valued at approximately $1,329,000. Luminus Management LLC bought a new stake in shares of Adicet Bio during the 4th quarter valued at $501,000. Burkehill Global Management LP acquired a new position in shares of Adicet Bio in the 4th quarter valued at $526,000. Squarepoint Ops LLC lifted its stake in shares of Adicet Bio by 20.0% in the 4th quarter. Squarepoint Ops LLC now owns 55,723 shares of the company’s stock valued at $469,000 after purchasing an additional 9,296 shares during the period. Finally, Susquehanna International Group LLP acquired a new position in shares of Adicet Bio in the 3rd quarter valued at $33,000. 83.89% of the stock is owned by institutional investors.

Trending Headlines about Adicet Bio

Here are the key news stories impacting Adicet Bio this week:

• Positive Sentiment: HC Wainwright significantly reduced its loss forecasts for 2026. The firm now expects Adicet Bio to lose $8.05 per share in fiscal 2026, compared with its previous estimate of a $11.58 loss. Its Q3 and Q4 2026 loss estimates were also improved to $2.05 and $2.12 per share, respectively, from $2.93 and $2.99.
• Positive Sentiment: Longer-term estimates also point to gradual improvement. HC Wainwright forecasts a $7.67 per-share loss for fiscal 2027, with quarterly losses narrowing from $2.19 in the first quarter to $1.78 by the third quarter and $1.83 in the fourth quarter.
• Positive Sentiment: Zacks upgraded Adicet Bio to Rank #2, or “Buy,” citing improving earnings prospects. The upgrade could encourage additional near-term buying. All You Need to Know About Adicet Bio Rating Upgrade to Buy
• Neutral Sentiment: Short-interest data provided no meaningful signal. Reported short interest was zero shares, making the stated increase and short-interest ratio unusable for assessing potential short-covering activity.
• Negative Sentiment: Adicet Bio is still expected to post substantial losses. HC Wainwright’s forecasts remain below zero through 2027, while the broader consensus calls for an $8.52 per-share loss in the current year. The company’s recent quarterly loss also exceeded analyst expectations, underscoring continuing execution and financing risks.

About Adicet Bio

Adicet Bio, Inc (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.